Ayahuasca is a beverage of indigenous origin made from Banisteriopsis caapi, which contains β-carboline alkaloids (harmine, harmaline, tetrahydroharmine), and Psychotria viridis, which contains N,N-dimethyltryptamine (DMT). The β-carbolines inhibit monoamine oxidase, enabling oral DMT bioavailability and characteristic psychoactive effects. This study analyzed the secondary compounds of the plants to examine pharmacokinetic and toxicological information. Molecular structures from PubChem were assessed using Swiss Target Prediction, Protox 3.0, and PreADMET platforms. The compounds show significant pharmacological potential but also toxicological risks that should not be overlooked, reinforcing the need for further in vivo and clinical studies.
LSD, traditionally known for its psychedelic effects, is gaining scientific interest for therapeutic potential in neurological and psychiatric disorders. This review highlights evidence that LSD promotes neuroplasticity, modulates the serotonergic system, and induces changes in brain connectivity. Microdosing may improve creativity, focus, and emotional well-being without hallucinogenic effects. The literature review indicates that, despite regulatory and safety challenges, LSD shows promising therapeutic potential when administered in controlled settings with professional guidance. More controlled studies are needed to fully understand its mechanisms and validate clinical efficacy.